The rise of venture debt and when biotechs should—and shouldn't—use it

Biotechs are operating on razor-thin margins, struggling in a market that just two years ago was flush with cash for big ideas. But now, these same companies are facing more desperate times and seeking out innovative ways to extend their cash runways. There's a time and a place for everything, and right now might be the time for venture debt.